Oculis Appoints Sharon Klier, M.D., M.S., M.P.H. as Chief Development Officer
Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company focused on eye care, has appointed Dr. Sharon Klier as Chief Development Officer. With over 20 years of experience in ophthalmology clinical development, Dr. Klier will oversee Oculis' ophthalmology pipeline. Her expertise spans early and late-stage programs, regulatory submissions, and approvals, particularly in retinal diseases, neuro-ophthalmology, and ocular inflammation.
Prior to joining Oculis, Dr. Klier served as Chief Development Officer, Head of Ophthalmology at UNITY Biotechnology. She has also held roles at Quark, Allergan, ISTA, and Pfizer. Oculis CEO Dr. Riad Sherif expressed confidence that Dr. Klier's expertise will be important in progressing the company's late-stage pipeline and executing its strategic vision.
Oculis Holding AG (Nasdaq: OCS), una società biofarmaceutica globale focalizzata sulla cura degli occhi, ha nominato il Dr. Sharon Klier come Chief Development Officer. Con oltre 20 anni di esperienza nello sviluppo clinico in oftalmologia, il Dr. Klier supervisionerà il portafoglio oftalmologico di Oculis. La sua esperienza copre programmi in fase iniziale e avanzata, presentazioni normative e approvazioni, in particolare nelle malattie retiniche, nella neurooftalmologia e nell'infiammazione oculare.
Prima di unirsi a Oculis, il Dr. Klier ha ricoperto il ruolo di Chief Development Officer e Responsabile dell'Oftalmologia presso UNITY Biotechnology. Ha anche ricoperto ruoli in Quark, Allergan, ISTA e Pfizer. Il CEO di Oculis, Dr. Riad Sherif, ha espresso fiducia che l'esperienza del Dr. Klier sarà fondamentale per il progresso del portafoglio in fase avanzata dell'azienda e per l'attuazione della sua visione strategica.
Oculis Holding AG (Nasdaq: OCS), una empresa biofarmacéutica global centrada en el cuidado ocular, ha designado a la Dra. Sharon Klier como Directora de Desarrollo. Con más de 20 años de experiencia en el desarrollo clínico de oftalmología, la Dra. Klier supervisará la cartera de oftalmología de Oculis. Su experiencia abarca programas en etapas tempranas y avanzadas, presentaciones regulatorias y aprobaciones, especialmente en enfermedades de la retina, neuro-oftalmología e inflamación ocular.
Antes de unirse a Oculis, la Dra. Klier fue Directora de Desarrollo y Jefa de Oftalmología en UNITY Biotechnology. También ha ocupado cargos en Quark, Allergan, ISTA y Pfizer. El CEO de Oculis, Dr. Riad Sherif, expresó su confianza en que la experiencia de la Dra. Klier será importante para avanzar en la cartera en etapa avanzada de la empresa y ejecutar su visión estratégica.
Oculis Holding AG (Nasdaq: OCS)는 눈 관리에 중점을 둔 글로벌 생명공학 회사로, Sharon Klier 박사를 최고 개발 책임자로 임명했습니다. 20년 이상의 안과 임상 개발 경험을 지닌 Klier 박사는 Oculis의 안과 파이프라인을 감독할 예정입니다. 그녀의 전문성은 초기 및 후기 단계 프로그램, 규제 제출 및 승인, 특히 망막 질환, 신경안과 및 안구 염증 분야에 걸쳐 있습니다.
Oculis에 합류하기 전에 Klier 박사는 UNITY Biotechnology에서 최고 개발 책임자 및 안과 책임자를 역임했습니다. 그녀는 Quark, Allergan, ISTA 및 Pfizer에서도 역할을 맡았습니다. Oculis의 CEO인 Riad Sherif 박사는 Klier 박사의 전문성이 회사의 후기 단계 파이프라인을 발전시키고 전략적 비전을 실행하는 데 중요할 것이라고 확신을 표명했습니다.
Oculis Holding AG (Nasdaq: OCS), une entreprise biopharmaceutique mondiale axée sur les soins oculaires, a nommé le Dr. Sharon Klier au poste de Directrice du Développement. Avec plus de 20 ans d'expérience dans le développement clinique en ophtalmologie, le Dr. Klier supervisera le portefeuille ophtalmologique d'Oculis. Son expertise couvre les programmes en phase précoce et avancée, les soumissions et approbations réglementaires, notamment dans le domaine des maladies de la rétine, de la neuro-ophtalmologie et de l'inflammation oculaire.
Avant de rejoindre Oculis, le Dr. Klier a occupé le poste de Directrice du Développement et Responsable de l'Ophtalmologie chez UNITY Biotechnology. Elle a également occupé des postes chez Quark, Allergan, ISTA et Pfizer. Le CEO d'Oculis, Dr. Riad Sherif, a exprimé sa confiance dans le fait que l'expertise du Dr. Klier sera essentielle pour faire avancer le portefeuille en phase avancée de l'entreprise et pour exécuter sa vision stratégique.
Oculis Holding AG (Nasdaq: OCS), ein globales biopharmazeutisches Unternehmen mit dem Fokus auf Augengesundheit, hat Dr. Sharon Klier zur Chief Development Officer ernannt. Mit über 20 Jahren Erfahrung in der klinischen Entwicklung der Augenheilkunde wird Dr. Klier das augenheilkundliche Portfolio von Oculis überwachen. Ihre Expertise umfasst Programme in frühen und späten Phase, regulatorische Einreichungen und Genehmigungen, insbesondere bei Netzhauterkrankungen, Neuro-Ophtalmologie und okulären Entzündungen.
Vor ihrem Eintritt bei Oculis war Dr. Klier Chief Development Officer und Leiterin der Augenheilkunde bei UNITY Biotechnology. Sie hatte auch Positionen bei Quark, Allergan, ISTA und Pfizer inne. Der CEO von Oculis, Dr. Riad Sherif, äußerte sein Vertrauen, dass Dr. Kliers Expertise entscheidend für den Fortschritt des späten Portfolios des Unternehmens und die Umsetzung seiner strategischen Vision sein wird.
- Appointment of an experienced Chief Development Officer with over 20 years in ophthalmology
- Dr. Klier's expertise in regulatory submissions and approvals could accelerate product development
- Strengthening of the R&D team with leadership experienced in taking programs from discovery to approval
- None.
ZUG, Switzerland, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the appointment of Dr. Sharon Klier, an executive leader with extensive experience in clinical development across early and late-stage programs, regulatory submissions, and approvals, to the role of Chief Development Officer. In this key role, Dr. Klier will oversee and provide strategic leadership across the clinical development and operations of Oculis’ robust ophthalmology pipeline.
Dr. Klier has over 20 years’ experience developing and executing global clinical development strategies that have supported product approvals and successful launches in retina and corneal diseases. Before joining Oculis, she served as Chief Development Officer, Head of Ophthalmology at UNITY Biotechnology, where she played a key role in driving forward UNITY’s pipeline. Prior to that, Dr. Klier held roles of increasing responsibility at several companies including Quark, Allergan, ISTA and Pfizer, where she gained extensive experience in ophthalmology, particularly in retinal diseases, neuro-ophthalmology, and ocular inflammation.
Riad Sherif, M.D., Chief Executive Officer of Oculis: “We are delighted that Sharon is joining Oculis’ strong R&D team. Sharon’s breadth of knowledge in ophthalmology, alongside her expertise in drug development, will be crucial as we continue to progress our late-stage pipeline. Her leadership experience, along with her proven track record in taking programs from late discovery through regulatory approval, will be instrumental as we continue to successfully execute our strategic vision.”
Sharon Klier, M.D., M.S., M.P.H., Chief Development Officer of Oculis: “I am excited to join the Oculis team, and have been so impressed by the company’s innovative, diverse and successful pipeline. I look forward to applying my expertise in clinical development across the different clinical programs, and to working with this skilled and accomplished team to make significant strides towards delivering new and transformative therapies for eye diseases.”
-ENDS-
About Oculis
Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) purposefully driven to save sight and improve eye care. Oculis’ highly differentiated pipeline comprises multiple innovative product candidates in development. It includes OCS-01 eye drops, a topical candidate in Phase 3 development for diabetic macular edema (DME) and for treatment of inflammation and pain following ocular surgery; OCS-02, a topical biologic anti-TNFα eye drop candidate for dry eye disease (DED) and for non-infectious anterior uveitis; and OCS-05, a neuroprotective candidate for acute optic neuritis (AON). Headquartered in Switzerland and with operations in the US, Oculis’ goal is to improve the health and quality of life of patients worldwide. The company is led by an experienced management team with a successful track record and is supported by leading international healthcare investors.
For more information, please visit: www.oculis.com
Oculis Contacts
Ms. Sylvia Cheung, CFO
sylvia.cheung@oculis.com
Investor & Media Relations
LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com
1-212-915-2577
Cautionary Statement Regarding Forward Looking Statements
This press release contains forward-looking statements and information. For example, the potential of Oculis to deliver potentially new and transformative therapies for eye diseases; expected future milestones and catalysts; the potential benefits of Oculis’ executive leadership team additions; the initiation, timing, progress and results of Oculis’ clinical and preclinical studies; Oculis’ research and development programs, regulatory and business strategy, future development plans, and management; Oculis’ ability to advance product candidates into, and successfully complete, clinical trials; and the the timing or likelihood of regulatory filings and approvals, are forward-looking. All forward-looking statements are based on estimates and assumptions that, while considered reasonable by Oculis and its management, are inherently uncertain and are inherently subject to risks, variability and contingencies, many of which are beyond Oculis’ control. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. All forward-looking statements are subject to risks, uncertainties and other factors that may cause actual results to differ materially from those that we expected and/or those expressed or implied by such forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of Oculis, including those set forth in the Risk Factors section of Oculis’ annual report on Form 20-F and any other documents filed with the U.S. Securities and Exchange Commission (the “SEC”). Copies of these documents are available on the SEC’s website, www.sec.gov. Oculis undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
FAQ
Who is the new Chief Development Officer of Oculis (OCS)?
What is Dr. Sharon Klier's background before joining Oculis (OCS)?
What will be Dr. Sharon Klier's responsibilities at Oculis (OCS)?
How might Dr. Sharon Klier's appointment impact Oculis (OCS) pipeline development?
